Walcott BP, Peterson RT. Zebrafish models of cerebrovascular disease. J Cereb Blood Flow Metab. 2014;34(4):571-7. doi:10.1038/jcbfm.2014.27
Bennett DA, Yu L, De Jager PL. Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer’s disease. Biochem Pharmacol. 2014;88(4):617-30. doi:10.1016/j.bcp.2014.01.037
Okada Y, Wu D, Trynka G, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506(7488):376-81. doi:10.1038/nature12873
Lukens AK, Ross LS, Heidebrecht R, et al. Harnessing evolutionary fitness in Plasmodium falciparum for drug discovery and suppressing resistance. Proc Natl Acad Sci U S A. 2014;111(2):799-804. doi:10.1073/pnas.1320886110
Hyman SE. Revitalizing psychiatric therapeutics. Neuropsychopharmacology. 2014;39(1):220-9. doi:10.1038/npp.2013.181
Weïwer M, Lewis MC, Wagner FF, Holson EB. Therapeutic potential of isoform selective HDAC inhibitors for the treatment of schizophrenia. Future Med Chem. 2013;5(13):1491-508. doi:10.4155/fmc.13.141
Basu A, Bodycombe NE, Cheah JH, et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell. 2013;154(5):1151-1161. doi:10.1016/j.cell.2013.08.003
Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov. 2013;12(8):581-94. doi:10.1038/nrd4051
Hyman SE. Revolution stalled. Sci Transl Med. 2012;4(155):155cm11. doi:10.1126/scitranslmed.3003142
Wen Q, Goldenson B, Silver SJ, et al. Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL. Cell. 2012;150(3):575-89. doi:10.1016/j.cell.2012.06.032